Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00EHX
|
|||
Former ID |
DIB010281
|
|||
Drug Name |
TT-301
|
|||
Synonyms |
Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
Click to Show/Hide
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
Company |
Northwestern University
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H21N7
|
|||
Canonical SMILES |
C1CN(CCN1C2=NN=C(C=C2C3=CC=NC=C3)C4=CC=CC=C4)C5=NC=CC=N5
|
|||
InChI |
1S/C23H21N7/c1-2-5-19(6-3-1)21-17-20(18-7-11-24-12-8-18)22(28-27-21)29-13-15-30(16-14-29)23-25-9-4-10-26-23/h1-12,17H,13-16H2
|
|||
InChIKey |
ZPJGUEPHFXPAQF-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 886208-76-0
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01357421) Effects of TT301 on Cytokine Levels Post Endotoxin Challenge. U.S. National Institutes of Health. | |||
REF 2 | A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.